CN105640968B - 一种人参皂苷组合物及其应用 - Google Patents
一种人参皂苷组合物及其应用 Download PDFInfo
- Publication number
- CN105640968B CN105640968B CN201610023808.0A CN201610023808A CN105640968B CN 105640968 B CN105640968 B CN 105640968B CN 201610023808 A CN201610023808 A CN 201610023808A CN 105640968 B CN105640968 B CN 105640968B
- Authority
- CN
- China
- Prior art keywords
- group
- glycol
- dammarane
- alkene
- glucopyranosyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 282
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract description 141
- 150000001336 alkenes Chemical class 0.000 claims abstract description 60
- 150000001875 compounds Chemical class 0.000 claims abstract description 40
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 230000036039 immunity Effects 0.000 claims abstract description 9
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims abstract description 8
- QBBDFCFQBGMQAR-JGCYWCJJSA-N (3s,5s,9r,10r,13r,17r)-3,5,14-trihydroxy-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-1,2,3,4,9,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-6-one Chemical group C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CCC33O)C)C3=CC(=O)[C@@]21O QBBDFCFQBGMQAR-JGCYWCJJSA-N 0.000 claims abstract description 4
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 claims description 62
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 claims description 3
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 claims description 3
- 208000019065 cervical carcinoma Diseases 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 claims description 3
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- -1 pulvis Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims 1
- 229930182494 ginsenoside Natural products 0.000 abstract description 18
- 229940089161 ginsenoside Drugs 0.000 abstract description 17
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000126 substance Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000208340 Araliaceae Species 0.000 description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 description 8
- 235000008434 ginseng Nutrition 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 125000003827 glycol group Chemical group 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 2
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000026097 Factitious disease Diseases 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011499 joint compound Substances 0.000 description 1
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610023808.0A CN105640968B (zh) | 2016-01-14 | 2016-01-14 | 一种人参皂苷组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610023808.0A CN105640968B (zh) | 2016-01-14 | 2016-01-14 | 一种人参皂苷组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105640968A CN105640968A (zh) | 2016-06-08 |
CN105640968B true CN105640968B (zh) | 2019-03-19 |
Family
ID=56487453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610023808.0A Expired - Fee Related CN105640968B (zh) | 2016-01-14 | 2016-01-14 | 一种人参皂苷组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105640968B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107028961A (zh) * | 2017-03-30 | 2017-08-11 | 北京林业大学 | 一种含芒果苷类化合物的泡腾片药物制剂及其制备方法 |
CN108685931A (zh) * | 2018-07-02 | 2018-10-23 | 南京类人生物材料有限公司 | 具有降糖活性的人参皂苷组合物及其应用 |
CN110664821A (zh) * | 2019-11-08 | 2020-01-10 | 延边大学 | 人参二醇在制备抑制pd-l1、肿瘤细胞增殖蛋白的表达的药物中的应用 |
CN111467358B (zh) * | 2020-03-31 | 2021-05-14 | 陕西巨子生物技术有限公司 | 包含人参皂苷Rh3、PPD和Rh2的药物组合物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1553918A (zh) * | 2001-07-24 | 2004-12-08 | ����ҩҵ�ɷ�����˾ | 新型达玛烷皂苷配基,它们作为抗癌剂的应用和生产它们的方法 |
WO2005040189A1 (en) * | 2003-10-27 | 2005-05-06 | Panagin Pharmaceuticals Inc. | Novel dammarane sapogenins and their use as anti-cancer agents |
CA2481664A1 (en) * | 2004-09-30 | 2006-03-30 | William Jia | Prevention of breast cancer with novel selective estrogen receptor moldulators |
CN101054400A (zh) * | 2007-05-28 | 2007-10-17 | 尹建元 | 一种新人参二醇及其衍生物、其制备方法及其医药用途 |
CN101121741A (zh) * | 2006-08-07 | 2008-02-13 | 辽宁新中现代医药有限公司 | 20(R)-25-羟基-达玛烷型-3β,12β,20-三醇的制备方法 |
CN101199534A (zh) * | 2006-12-15 | 2008-06-18 | 中国科学院上海生命科学研究院 | 一种原人参二醇衍生物的抗肿瘤用途 |
CN101229175A (zh) * | 2008-02-15 | 2008-07-30 | 沈阳药科大学 | 一对原人参二醇衍生物和它们混合体的医药用途 |
-
2016
- 2016-01-14 CN CN201610023808.0A patent/CN105640968B/zh not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1553918A (zh) * | 2001-07-24 | 2004-12-08 | ����ҩҵ�ɷ�����˾ | 新型达玛烷皂苷配基,它们作为抗癌剂的应用和生产它们的方法 |
WO2005040189A1 (en) * | 2003-10-27 | 2005-05-06 | Panagin Pharmaceuticals Inc. | Novel dammarane sapogenins and their use as anti-cancer agents |
CA2481664A1 (en) * | 2004-09-30 | 2006-03-30 | William Jia | Prevention of breast cancer with novel selective estrogen receptor moldulators |
CN101121741A (zh) * | 2006-08-07 | 2008-02-13 | 辽宁新中现代医药有限公司 | 20(R)-25-羟基-达玛烷型-3β,12β,20-三醇的制备方法 |
CN101199534A (zh) * | 2006-12-15 | 2008-06-18 | 中国科学院上海生命科学研究院 | 一种原人参二醇衍生物的抗肿瘤用途 |
CN101054400A (zh) * | 2007-05-28 | 2007-10-17 | 尹建元 | 一种新人参二醇及其衍生物、其制备方法及其医药用途 |
CN101229175A (zh) * | 2008-02-15 | 2008-07-30 | 沈阳药科大学 | 一对原人参二醇衍生物和它们混合体的医药用途 |
Also Published As
Publication number | Publication date |
---|---|
CN105640968A (zh) | 2016-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Anticancer property of ginsenoside Rh2 from ginseng | |
CN105640968B (zh) | 一种人参皂苷组合物及其应用 | |
Miraj et al. | Astragalus membranaceus: A review study of its anti-carcinoma activities | |
Abdel-Salam et al. | Cytotoxicity of Luffa cylindrica (L.) M. Roem. extract against circulating cancer stem cells in hepatocellular carcinoma | |
CN103316096A (zh) | 一种黑种草子总黄酮提取物及其制备方法和用途 | |
Liu et al. | Functional mechanism of ginsenoside compound K on tumor growth and metastasis | |
Xu et al. | A review of anti-tumour effects of ginsenoside in gastrointestinal cancer | |
CN104586873B (zh) | 木蝴蝶苷a在制备治疗癌症药物中的应用 | |
CN100506233C (zh) | 一种藤梨根提取物及其抗癌用途 | |
CN103230388B (zh) | 鄂西香茶菜素作为Wnt信号通路抑制剂及抗癌药物的应用 | |
CN104286278A (zh) | 具有抗癌保健功能的中药速溶茶 | |
CN103610682A (zh) | 3α-羟基-30-齐墩果-12,20(29)-二烯-28-酸的制备方法和在制备抗肿瘤药物中的应用 | |
KR20180118413A (ko) | 밀리타리스 동충하초 부탄올 분획물을 유효성분으로 하는 간암의 예방 또는 치료용 조성물 | |
Carneiro et al. | Pfaffia paniculata (Brazilian ginseng) methanolic extract reduces angiogenesis in mice | |
CN106798892A (zh) | 一种具有增效减毒作用的化疗联合用抗肿瘤中药组合物及其应用 | |
CN104825763A (zh) | 一种中药组合物在制备逆转肿瘤多药耐药药物中的应用 | |
TW202206090A (zh) | 黃耆醫藥組合物用於增強癌症治療之用途 | |
CN103417620B (zh) | 溪黄草提取物作为stat3信号特异性抑制剂在制备抗肿瘤药物中的应用 | |
CN105924494B (zh) | 一类呋甾皂苷类化合物及其应用 | |
Yang et al. | Research Progress on the Pharmacological Effects and Clinical Application of Jupi Zhuru Decoction | |
CN104546952A (zh) | 一种石上柏活性组分及其制备方法和用途 | |
CN106543159B (zh) | 具有抗肿瘤活性的环氧型番荔枝内酯类化合物及其制备方法与应用 | |
CN104288142B (zh) | 木果楝素h及其类似物在制备抗抑郁症药物或食品中的用途 | |
CN103719993A (zh) | 一种玉米须降糖饮品及其制备方法 | |
CN103734840A (zh) | 一种绞股蓝降糖饮品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190626 Address after: 130012 No. 2699 Qianjin Street, Jilin, Changchun Patentee after: Jilin University Address before: 130021 5th Floor, Biopharmaceuticals Laboratory, Institute of Regeneration, School of Pharmacy, Jilin University, 1163 Xinmin Street, Changchun City, Jilin Province Co-patentee before: Sun Dejun Patentee before: Sun Miaonan |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190319 Termination date: 20220114 |